Overview

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this test).

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

BeiGene
Takeda Pharmaceutical Co. Limited

Treatments:

HMPL-013
tislelizumab